$MNPR
Monopar Therapeutics

2021 Q4 Form 10-K Financial Statement

#000165495422003701 Filed on March 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $698.4K $2.634M $630.0K
YoY Change 10.86% 7.95% -1.56%
% of Gross Profit
Research & Development $1.983M $6.493M $1.630M
YoY Change 21.64% 59.73% 181.03%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.681M $9.127M $2.260M
YoY Change 18.63% 40.23% 85.25%
Operating Profit -$9.127M
YoY Change 40.23%
Interest Expense $530.00 $24.02K $10.00K
YoY Change -94.7% -69.98% -50.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $120.0K
YoY Change -100.0%
Pretax Income -$2.681M -$9.103M -$2.130M
YoY Change 25.85% 44.5% 76.03%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.681M -$9.103M -$2.130M
YoY Change 25.85% 44.39% 76.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$212.9K -$729.9K -$185.9K
COMMON SHARES
Basic Shares Outstanding 12.59M shares 12.47M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.30M $20.30M $16.74M
YoY Change 21.29% 21.29% 26.72%
Cash & Equivalents $20.30M $20.30M $16.74M
Short-Term Investments
Other Short-Term Assets $217.7K $217.8K $62.69K
YoY Change 247.34% 262.92% 213.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $20.52M $20.52M $16.80M
YoY Change 22.15% 22.15% 26.99%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $68.86K
YoY Change -100.0% -100.0% -43.73%
Total Long-Term Assets $0.00 $0.00 $68.86K
YoY Change -100.0% -100.0% -43.73%
TOTAL ASSETS
Total Short-Term Assets $20.52M $20.52M $16.80M
Total Long-Term Assets $0.00 $0.00 $68.86K
Total Assets $20.52M $20.52M $16.87M
YoY Change 21.66% 21.65% 26.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.581M $1.581M $1.180M
YoY Change 33.94% 33.94% 63.89%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.581M $1.581M $1.180M
YoY Change 33.94% 33.94% 62.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.581M $1.581M $1.180M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.581M $1.581M $1.177M
YoY Change 34.32% 33.94% 62.49%
SHAREHOLDERS EQUITY
Retained Earnings -$41.29M -$32.19M
YoY Change 28.28% 24.36%
Common Stock $12.60K $11.45K
YoY Change 10.0% 8.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.94M $18.94M $15.69M
YoY Change
Total Liabilities & Shareholders Equity $20.52M $20.52M $16.87M
YoY Change 21.66% 21.65% 26.34%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$2.681M -$9.103M -$2.130M
YoY Change 25.85% 44.39% 76.03%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.032M $7.317M -$1.240M
YoY Change 63.86% -256.95% 85.07%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -7.770K $10.88M -10.00K
YoY Change -22.3% 32.97% -100.11%
NET CHANGE
Cash From Operating Activities -2.032M $7.317M -1.240M
Cash From Investing Activities $0.00
Cash From Financing Activities -7.770K $10.88M -10.00K
Net Change In Cash -2.040M $18.20M -1.250M
YoY Change 63.17% 416.98% -114.33%
FREE CASH FLOW
Cash From Operating Activities -$2.032M $7.317M -$1.240M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.47
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1258577 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.47
CY2021 dei Auditor Location
AuditorLocation
Walnut Creek, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20303869 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16737109 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
217745 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
62690 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
20521614 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
16799799 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
68858 USD
CY2021Q4 us-gaap Assets
Assets
20521614 USD
CY2020Q4 us-gaap Assets
Assets
16868657 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1580543 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1176666 USD
CY2021Q4 us-gaap Liabilities
Liabilities
1580543 USD
CY2020Q4 us-gaap Liabilities
Liabilities
1176666 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12598125 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11453465 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12598 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
11453 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60220016 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47873570 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3160 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7873 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41288383 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32185159 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18941071 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15691991 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20521614 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16868657 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6493208 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4065199 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2634040 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2443676 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
9127248 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
6508875 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-9127248 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-6508875 USD
CY2021 us-gaap Other Income
OtherIncome
0 USD
CY2020 us-gaap Other Income
OtherIncome
122400 USD
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
24024 USD
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
81902 USD
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4713 USD
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
3097 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9098511 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6301476 USD
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12472217 shares
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10958256 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
12627856 USD
CY2020 mnpr Issuance Of Common Stock Under A Capital On Demandtm Sales Agreement With Jonestrading Institutional Services Llc Net Of Commissions And Fees Of One Six Two Eight Four Amount
IssuanceOfCommonStockUnderACapitalOnDemandtmSalesAgreementWithJonestradingInstitutionalServicesLlcNetOfCommissionsAndFeesOfOneSixTwoEightFourAmount
8175291 USD
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1320890 USD
CY2020 mnpr Offering Costs
OfferingCosts
-130570 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3097 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15691991 USD
CY2021 mnpr Issuance Of Common Stock Under A Capital On Demandtm Sales Agreement With Jonestrading Institutional Services Llc Net Of Commissions And Fees Three Three Eight One Five Three Amount
IssuanceOfCommonStockUnderACapitalOnDemandtmSalesAgreementWithJonestradingInstitutionalServicesLlcNetOfCommissionsAndFeesThreeThreeEightOneFiveThreeAmount
10925312 USD
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2021 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-63253 USD
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17478 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1468054 USD
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4713 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18941071 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-9103224 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-6304573 USD
CY2021 mnpr Stock Based Compensation Expense Non Cash
StockBasedCompensationExpenseNonCash
1468054 USD
CY2020 mnpr Stock Based Compensation Expense Non Cash
StockBasedCompensationExpenseNonCash
1320890 USD
CY2021 mnpr Other Income From Ppp Loans Forgiveness
OtherIncomeFromPppLoansForgiveness
0 USD
CY2020 mnpr Other Income From Ppp Loans Forgiveness
OtherIncomeFromPppLoansForgiveness
-122400 USD
CY2021 mnpr Other Currents Assets
OtherCurrentsAssets
-86198 USD
CY2020 mnpr Other Currents Assets
OtherCurrentsAssets
-3789 USD
CY2021 mnpr Accounts Payable Accrued Expenses And Other Current Liabilities
AccountsPayableAccruedExpensesAndOtherCurrentLiabilities
403967 USD
CY2020 mnpr Accounts Payable Accrued Expenses And Other Current Liabilities
AccountsPayableAccruedExpensesAndOtherCurrentLiabilities
447598 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7317401 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4662274 USD
CY2021 mnpr Cash Proceeds From The Sales Of Common Stock Under A Capital
CashProceedsFromTheSalesOfCommonStockUnderACapital
10925312 USD
CY2020 mnpr Cash Proceeds From The Sales Of Common Stock Under A Capital
CashProceedsFromTheSalesOfCommonStockUnderACapital
8175291 USD
CY2021 us-gaap Payments For Fees
PaymentsForFees
0 USD
CY2020 us-gaap Payments For Fees
PaymentsForFees
115571 USD
CY2021 mnpr Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits
63253 USD
CY2020 mnpr Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfVestedRestrictedStockUnits
0 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17478 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2021 mnpr Ppp Forgivable Bank Loan
PppForgivableBankLoan
0 USD
CY2020 mnpr Ppp Forgivable Bank Loan
PppForgivableBankLoan
122400 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10879537 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8182120 USD
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
4624 USD
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
3334 USD
CY2021 mnpr Net Increase In Cash And Cash Equivalents
NetIncreaseInCashAndCashEquivalents
3566760 USD
CY2020 mnpr Net Increase In Cash And Cash Equivalents
NetIncreaseInCashAndCashEquivalents
3523180 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16737109 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13213929 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20303869 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16737109 USD
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-11099 USD
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 1 - Nature of Business and Liquidity</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Nature of Business</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em> </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Monopar Therapeutics Inc. (“Monopar” or the ”Company”) is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve quality of life for cancer patients. Monopar currently has four compounds in development: 1) Validive<sup>®</sup> (clonidine hydrochloride mucobuccal tablet; clonidine HCI MBT), a Phase 2b/3 clinical stage, first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (“SOM”) in oropharyngeal cancer patients; 2) camsirubicin (generic name for MNPR-201, GPX-150; 5-imino-13-deoxydoxorubicin), a Phase 1b clinical stage novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; 3) MNPR-101, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for advanced cancers and severe COVID-19; and 4) an early stage camsirubicin analog, MNPR-202, for various cancers. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Liquidity</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred an accumulated deficit of approximately $41.3 million as of December 31, 2021. To date, the Company has primarily funded its operations with the net proceeds from the Company’s initial public offering of its common stock on Nasdaq, sales of its common stock in the public market through an at-the-market sales agreement, private placements of convertible preferred stock and of common stock and cash provided in the camsirubicin asset purchase transaction. Management estimates that currently available cash will provide sufficient funds to enable the Company to meet its obligations at least through March 2023. The Company’s ability to fund its future operations, including the continued clinical development of Validive and camsirubicin, is dependent upon its ability to execute its business strategy, to obtain additional funding and/or to execute collaborative research agreements. There can be no certainty that future financing or collaborative research agreements will occur in the amounts required or at a time needed to maintain operations, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The coronavirus disease (“COVID-19”) pandemic continues to affect economies and business around the world. In response to COVID-19 and its effects on clinical trials, in 2020 Monopar modified the original adaptive design Phase 3 clinical trial for its lead product candidate, Validive, to be a Phase 2b/3 clinical trial (“VOICE”) to better fit the types of trials which can enroll sufficient required patients in the current environment. This modification allowed the Company to activate the VOICE clinical trial without requiring near-term financing. To complete the VOICE clinical program, including, if required, completing a second Phase 3 confirmatory clinical trial, Monopar will require additional funding in the millions or tens of millions of dollars (depending on if the Company has consummated a collaboration or partnership or neither for Validive), which it is planning to pursue within the next 12 months. Due to many uncertainties, the Company is unable to estimate the pandemic’s financial impact or duration in light of global vaccine rollouts and adverse new cases surging from COVID-19 variants at this time, or its potential impact on the Company’s current clinical trials, including COVID-19’s effect on drug candidate manufacturing, shipping, patient recruitment at clinical sites and regulatory agencies around the globe. </p>
CY2021Q4 mnpr Retained Earning Accumulated Deficit
RetainedEarningAccumulatedDeficit
41300000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </p>
CY2021Q4 mnpr Insurance Premiums Dues Subscription And Software Cost Paid In Advance
InsurancePremiumsDuesSubscriptionAndSoftwareCostPaidInAdvance
10000 USD
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company maintains cash and cash equivalents at two reputable financial institutions. As of December 31, 2021, the balance at one financial institution was in excess of the $250,000 Federal Deposit Insurance Corporation (“FDIC”) insurable limit. The Company has not experienced any losses on its deposits since inception and management believes the Company is not exposed to significant risks with respect to these financial institutions.</p>
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
20014205 USD
CY2021Q4 us-gaap Cash
Cash
20014205 USD
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16605682 USD
CY2020Q4 us-gaap Cash
Cash
16605682 USD
CY2021 mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
12472217 shares
CY2020 mnpr Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
10958256 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1655451 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1298643 shares
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.13
CY2020 mnpr Stock Options Forfeite
StockOptionsForfeite
-3243 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021 mnpr Common Stock Aggregate Offering Price Description
CommonStockAggregateOfferingPriceDescription
up to $19.7
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1964724 shares
mnpr Average Gross Price Per Share
AverageGrossPricePerShare
10.02
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
19100603 USD
mnpr Fees And Commission
FeesAndCommission
591188 USD
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12598125 shares
CY2021 mnpr Aggregate Stock Option Purchase Of Shares
AggregateStockOptionPurchaseOfShares
403476 shares
CY2021 mnpr Description Of Exercise Price
DescriptionOfExercisePrice
exercise prices ranging from $4.01 to $9.67 per share which vest over 1 to 4 years
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
124374 shares
CY2021 us-gaap Standby Bond Purchase Commitment Expiration Period
StandbyBondPurchaseCommitmentExpirationPeriod
P10Y
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.94
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
174357 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.27
CY2021 mnpr Stock Options Forfeite
StockOptionsForfeite
-115151 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.49
CY2021 mnpr Stock Options Exercised
StockOptionsExercised
-2913 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1543989 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
403476 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.78
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
345286 shares
CY2021 mnpr Weighted Average Exercise Price Unvested Options Outstanding Expected To Vest
WeightedAverageExercisePriceUnvestedOptionsOutstandingExpectedToVest
7.28
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1543989 shares
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1198703 shares
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M19D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
403476 shares
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
174357 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.46
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.03
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
1152572 USD
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
1214512 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1800000 USD
CY2021Q4 mnpr Weighted Average Exercise Price
WeightedAverageExercisePrice
4.78
CY2021Q4 mnpr Weighted Average Vested Exercise Price
WeightedAverageVestedExercisePrice
4.06
CY2021Q4 mnpr Weighted Average Exercise Price Of Unvested Expected To Vest Share
WeightedAverageExercisePriceOfUnvestedExpectedToVestShare
7.28
CY2021Q4 mnpr Unamortized Unvested Balance Of Stock Base Compensation
UnamortizedUnvestedBalanceOfStockBaseCompensation
2500000 USD
CY2021 mnpr Unamortized Unvested Balance Of Stock Base Compensation Period
UnamortizedUnvestedBalanceOfStockBaseCompensationPeriod
P2Y7M6D
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
18361 USD
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2500000 USD
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2652000 USD
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
18361 USD
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18361 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0712 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0203 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0197 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2747 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0071 pure
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3484229 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1951673 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
382648 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
228922 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
700208 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
611903 USD
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3153199 USD
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2427668 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7720284 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5220166 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7720284 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5220166 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2021 mnpr Beginning Uncertain Tax Benefits Balance
BeginningUncertainTaxBenefitsBalance
63262 USD
CY2020 mnpr Beginning Uncertain Tax Benefits Balance
BeginningUncertainTaxBenefitsBalance
0 USD
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
46092 USD
CY2020 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
44786 USD
CY2021 mnpr Prior Year Increases Decreases
PriorYearIncreasesDecreases
-6250 USD
CY2020 mnpr Prior Year Increases Decreases
PriorYearIncreasesDecreases
18476 USD
CY2021 mnpr Ending Uncertain Tax Benefits
EndingUncertainTaxBenefits
103104 USD
CY2020 mnpr Ending Uncertain Tax Benefits
EndingUncertainTaxBenefits
63262 USD
CY2021Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
103104 USD
CY2021 mnpr License Agreement Fee
LicenseAgreementFee
1000000 USD
CY2021 mnpr Operating Lease Monthly Payment
OperatingLeaseMonthlyPayment
4487 USD
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
54960 USD
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
55236 USD

Files In Submission

Name View Source Status
0001654954-22-003701-index-headers.html Edgar Link pending
0001654954-22-003701-index.html Edgar Link pending
0001654954-22-003701.txt Edgar Link pending
0001654954-22-003701-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mnpr-20211231.xsd Edgar Link pending
mnpr-20211231_cal.xml Edgar Link unprocessable
mnpr-20211231_def.xml Edgar Link unprocessable
mnpr-20211231_lab.xml Edgar Link unprocessable
mnpr-20211231_pre.xml Edgar Link unprocessable
mnpr_10k.htm Edgar Link pending
mnpr_10kimg1.jpg Edgar Link pending
mnpr_10kimg10.jpg Edgar Link pending
mnpr_10kimg11.jpg Edgar Link pending
mnpr_10kimg12.jpg Edgar Link pending
mnpr_10kimg14.jpg Edgar Link pending
mnpr_10kimg3.jpg Edgar Link pending
mnpr_10kimg4.jpg Edgar Link pending
mnpr_10kimg5.jpg Edgar Link pending
mnpr_10kimg6.jpg Edgar Link pending
mnpr_10kimg7.jpg Edgar Link pending
mnpr_10kimg8.jpg Edgar Link pending
mnpr_10kimg9.jpg Edgar Link pending
mnpr_10k_htm.xml Edgar Link completed
mnpr_ex101.htm Edgar Link pending
mnpr_ex102.htm Edgar Link pending
mnpr_ex103.htm Edgar Link pending
mnpr_ex104.htm Edgar Link pending
mnpr_ex105.htm Edgar Link pending
mnpr_ex106.htm Edgar Link pending
mnpr_ex107.htm Edgar Link pending
mnpr_ex108.htm Edgar Link pending
mnpr_ex211.htm Edgar Link pending
mnpr_ex231.htm Edgar Link pending
mnpr_ex311.htm Edgar Link pending
mnpr_ex312.htm Edgar Link pending
mnpr_ex321.htm Edgar Link pending
mnpr_ex41.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending